Emergent BioSolutions (STU:ER4) ROCE %: 8.33% (As of Mar. 2026)

What is Emergent BioSolutions ROCE %?

Emergent BioSolutions STU:ER4 +5.77% 51 ROCE % is 8.33% as of Mar. 2026. GuruFocus rates STU:ER4 with a GF Score™ of 51/100 and a GF Value™ of €4.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Emergent BioSolutions's annualized ROCE % for the quarter that ended in Mar. 2026 was 8.33%.

Emergent BioSolutions (STU:ER4) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Emergent BioSolutions ROCE % Related Terms

Emergent BioSolutions ROCE % Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions ROCE % Chart

Emergent BioSolutions Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

13.77

-8.34

-40.63

-6.11

11.11

Emergent BioSolutions Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															33.29	-0.62	22.08	-11.48	8.33

51GF Score

Emergent BioSolutions Inc STU:ER4

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Emergent BioSolutions ROCE % Calculation

Emergent BioSolutions's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	121.353	/	( ( (1327.164 - 155.092)	+	(1126.084 - 112.899) )	/ 2 )
	=	121.353	/	( (1172.072	+	1013.185)	/ 2 )
	=	121.353	/	1092.6285
	=	11.11 %

Emergent BioSolutions's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	84.424	/	( ( (1126.084 - 112.899)	+	(1142.146 - 128.625) )	/ 2 )
	=	84.424	/	( ( 1013.185	+	1013.521 )	/ 2 )
	=	84.424	/	1013.353
	=	8.33 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 8.33% mean?

Emergent BioSolutions (STU:ER4) has a ROCE % of 8.33% as of Mar. 2026.

Is Emergent BioSolutions' ROCE % too high?

Emergent BioSolutions' current ROCE % is 8.33%. The Drug Manufacturers industry median ROCE % is 7.00. Emergent BioSolutions' value of 8.33% is 19.1% above this industry median. Overall, Emergent BioSolutions has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Emergent BioSolutions' ROCE % compare to AQST and EOLS?

Emergent BioSolutions' ROCE % of 8.33% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Emergent BioSolutions' value of 8.33% is 19.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current ROCE % of 8.33% is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current ROCE % is 8.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Emergent BioSolutions stock overvalued right now?

Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.05, compared to a current price of €7.34 — trading 81.1% above its estimated fair value. The current ROCE % is 8.33% and 19.1% above the Drug Manufacturers industry median of 7.00. Emergent BioSolutions' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current ROCE % is 8.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €7.34 is trading 81.1% above its estimated GF Value™ of €4.05. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for STU:ER4:

ROCE %: 8.33%
GF Value™: €4.05 vs. price of €7.34 (81.1% above fair value)
GF Score™: 51/100 with 5 warning signs
Industry Position: 19.1% above the Drug Manufacturers median

No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies AQST EOLS ELTP IRWD SIGA ORGO TKNO TLRY AKBA NIKA XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges EBS:USA 0IGA:UK

Address 300 Professional Drive, Gaithersburg, MD, USA, 20879

Website https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

51GF Score

Get the complete analysis for STU:ER4

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.34

Price

€4.05

GF Value

View STU:ER4 Analysis

See ROCE % data for all stocks →